Literature DB >> 2760478

Rapid isolation and characterization of native mouse complement components C3 and C5.

C W Van den Berg1, H Van Dijk, P J Capel.   

Abstract

A rapid, 1 day procedure for the purification of mouse complement factors C3 and C5 is described. The method is based on fractionated precipitation by polyethylene glycol 6000, followed by Mono Q anion exchange chromatography on a system for fast protein liquid chromatography (FPLC). For C3 isolation, an additional FPLC separation step using Superose 12 (gel filtration) was used. C3 was purified 71-fold with a yield of 32% as measured by biological activity; the preparation contained no detectable contaminants as judged by SDS-PAGE. A comparable procedure for the isolation of C5 resulted in a preparation with a considerable contamination which could be easily removed by affinity chromatography using antibodies directed against these contaminants. With this combined procedure C5 was purified 536-fold with a yield of 28% based on biological activity. SDS-polyacrylamide gel electrophoresis revealed that mouse C3 and C5 had apparent Mrs of 170,000 and 190,000, respectively. Under reducing conditions the alpha and beta chains showed Mrs of 107,000 and 62,000 for C3, and 104,000 and 85,000 for C5.

Entities:  

Mesh:

Substances:

Year:  1989        PMID: 2760478     DOI: 10.1016/0022-1759(89)90336-0

Source DB:  PubMed          Journal:  J Immunol Methods        ISSN: 0022-1759            Impact factor:   2.303


  9 in total

1.  Slp is an essential component of an EDTA-resistant activation pathway of mouse complement.

Authors:  C W van den Berg; P Démant; P C Aerts; H Van Dijk
Journal:  Proc Natl Acad Sci U S A       Date:  1992-11-15       Impact factor: 11.205

2.  Increased immunogenicity and induction of class switching by conjugation of complement C3d to pneumococcal serotype 14 capsular polysaccharide.

Authors:  S T Test; J Mitsuyoshi; C C Connolly; A H Lucas
Journal:  Infect Immun       Date:  2001-05       Impact factor: 3.441

3.  Epitope mapping of 10 monoclonal antibodies against the pig analogue of human membrane cofactor protein (MCP).

Authors:  J M Pérez De La Lastra; C W Van Den Berg; R Bullido; F Almazán; J Domínguez; D Llanes; B P Morgan
Journal:  Immunology       Date:  1999-04       Impact factor: 7.397

4.  Innate immune defense against pneumococcal pneumonia requires pulmonary complement component C3.

Authors:  Alison R Kerr; Gavin K Paterson; Alan Riboldi-Tunnicliffe; Tim J Mitchell
Journal:  Infect Immun       Date:  2005-07       Impact factor: 3.441

5.  Induction of active immunological hypo/non-responsiveness to C5 in adult C5-deficient DBA/2 mice.

Authors:  C W van den Berg; F M Hofhuis; P M Rademaker; H van Dijk
Journal:  Immunology       Date:  1991-11       Impact factor: 7.397

6.  Complement C3 and C5 play critical roles in traumatic brain cryoinjury: blocking effects on neutrophil extravasation by C5a receptor antagonist.

Authors:  Diane L Sewell; Brendon Nacewicz; Frances Liu; Sinarack Macvilay; Anna Erdei; John D Lambris; Matyas Sandor; Zsuzsa Fabry
Journal:  J Neuroimmunol       Date:  2004-10       Impact factor: 3.478

7.  C3- and T-cell-dependent adjuvant activity of in vivo formed immune complexes.

Authors:  C W Van den Berg; M A Hazenberg; F M Hofhuis; S M Van Rooyen; H Van Dijk
Journal:  Immunology       Date:  1991-07       Impact factor: 7.397

8.  Hyperfunctional complement C3 promotes C5-dependent atypical hemolytic uremic syndrome in mice.

Authors:  Kate Smith-Jackson; Yi Yang; Harriet Denton; Isabel Y Pappworth; Katie Cooke; Paul N Barlow; John P Atkinson; M Kathryn Liszewski; Matthew C Pickering; David Kavanagh; H Terence Cook; Kevin J Marchbank
Journal:  J Clin Invest       Date:  2019-02-04       Impact factor: 14.808

9.  A novel mechanism for hypofibrinolysis in diabetes: the role of complement C3.

Authors:  K Hess; S H Alzahrani; M Mathai; V Schroeder; A M Carter; G Howell; T Koko; M W J Strachan; J F Price; K A Smith; P J Grant; R A Ajjan
Journal:  Diabetologia       Date:  2011-09-15       Impact factor: 10.122

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.